Autophagy as a new therapeutic target in Duchenne muscular dystrophy

[1]  S. Matecki,et al.  AMPK activation stimulates autophagy and ameliorates muscular dystrophy in the mdx mouse diaphragm. , 2012, The American journal of pathology.

[2]  E. Clementi,et al.  Nitric Oxide in Myogenesis and Therapeutic Muscle Repair , 2012, Molecular Neurobiology.

[3]  K. Davies,et al.  Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy. , 2012, Current gene therapy.

[4]  N. Bresolin,et al.  Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. , 2012, Pharmacological research.

[5]  A. Muotri,et al.  Autophagy in Stem Cell Maintenance and Differentiation , 2012, Stem cells and development.

[6]  F. Muntoni,et al.  Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  J. Grieger,et al.  Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  E. Clementi,et al.  A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy , 2011, Pharmacological research.

[9]  S. Jhunjhunwala,et al.  Rapamycin Ameliorates Dystrophic Phenotype in mdx Mouse Skeletal Muscle , 2011, Molecular medicine.

[10]  K. Davies,et al.  Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[12]  M. Sandri,et al.  Autophagy induction rescues muscular dystrophy , 2011, Autophagy.

[13]  N. Maraldi,et al.  Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration , 2010, Nature Medicine.

[14]  E. Clementi,et al.  Co‐administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans , 2010, British journal of pharmacology.

[15]  M. Emborg,et al.  Evaluation of hydrodynamic limb vein injections in nonhuman primates. , 2010, Human gene therapy.

[16]  M. Sandri.  Autophagy in skeletal muscle , 2010, FEBS letters.

[17]  L. Schaeffer,et al.  Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy , 2009, The Journal of cell biology.

[18]  D. Metzger,et al.  Autophagy is required to maintain muscle mass. , 2009, Cell metabolism.

[19]  G. Brunelli,et al.  Glutamatergic Reinnervation and Assembly of Glutamatergic Synapses in Adult Rat Skeletal Muscle Occurs at Cholinergic Endplates , 2009, Journal of neuropathology and experimental neurology.

[20]  T. Proikas-Cezanne,et al.  Control of autophagy initiation by phosphoinositide 3‐phosphatase jumpy , 2009, The EMBO journal.

[21]  C. Mammucari,et al.  Smad2 and 3 transcription factors control muscle mass in adulthood. , 2009, American journal of physiology. Cell physiology.

[22]  V. Hill,et al.  Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. , 2008, Human molecular genetics.

[23]  E. Clementi,et al.  HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment , 2008, Proceedings of the National Academy of Sciences.

[24]  C. Mammucari,et al.  Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle , 2008, Autophagy.

[25]  H. Sweeney,et al.  Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy , 2008, Nature Medicine.

[26]  John L Cleveland,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes , 2008, Autophagy.

[27]  Masaaki Komatsu,et al.  Homeostatic Levels of p62 Control Cytoplasmic Inclusion Body Formation in Autophagy-Deficient Mice , 2007, Cell.

[28]  A. Goldberg,et al.  FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. , 2007, Cell metabolism.

[29]  A. Goldberg,et al.  FoxO3 controls autophagy in skeletal muscle in vivo. , 2007, Cell metabolism.

[30]  E. Clementi,et al.  Necdin mediates skeletal muscle regeneration by promoting myoblast survival and differentiation , 2007, The Journal of cell biology.

[31]  Guido Kroemer,et al.  Self-eating and self-killing: crosstalk between autophagy and apoptosis , 2007, Nature Reviews Molecular Cell Biology.

[32]  E. Clementi,et al.  Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy , 2007, Proceedings of the National Academy of Sciences.

[33]  E. Clementi,et al.  Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy , 2006, Journal of Cell Science.

[34]  S. Fortuni,et al.  Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors , 2006, Nature Medicine.

[35]  C. Dogra,et al.  Regulation of phosphatidylinositol 3‐kinase (PI3K)/Akt and nuclear factor‐kappa B signaling pathways in dystrophin‐deficient skeletal muscle in response to mechanical stretch , 2006, Journal of cellular physiology.

[36]  Angela K. Peter,et al.  Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway. , 2006, Experimental cell research.

[37]  V. Dubowitz.  Prednisone for Duchenne muscular dystrophy , 2005, The Lancet Neurology.

[38]  Daniel J. Klionsky,et al.  Autophagy in Health and Disease: A Double-Edged Sword , 2004, Science.

[39]  M. Matsui,et al.  In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. , 2003, Molecular biology of the cell.

[40]  F. Muntoni,et al.  Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research , 2002, Neuromuscular Disorders.

[41]  E. Calabria,et al.  A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Emery,et al.  The muscular dystrophies , 2002, The Lancet.

[43]  K. Ohlendieck,et al.  Drastic reduction of calsequestrin-like proteins and impaired calcium binding in dystrophic mdx muscle. , 2002, Journal of applied physiology.

[44]  G. Yancopoulos,et al.  Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo , 2001, Nature Cell Biology.

[45]  A. Nishikawa,et al.  Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. , 1995, Journal of biochemistry.

[46]  C. Carlson,et al.  A noninvasive procedure to detect muscle weakness in the mdx mouse , 1990, Muscle & nerve.

[47]  E. Homsher,et al.  Skeletal muscle energetics and metabolism. , 1978, Annual review of physiology.

[48]  D. Leroith,et al.  Skeletal muscle. , 2005, Advances in experimental medicine and biology.

[49]  A. Manzur,et al.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2004, The Cochrane database of systematic reviews.